Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | JUN | P05412 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28522737 | 0.86 | TBXAS1 (0.57) | MAPTRAB9AKDM4ENPC1JUN | |
| SCHEMBL14682626 | 0.85 | MAPT (0.53) | MAPTRAB9AKDM4ENPC1JUN | |
| SCHEMBL28340936 | 0.85 | MAPT (0.53) | MAPTRAB9AKDM4ENPC1JUN | |
| SCHEMBL28450581 | 0.82 | LMNA (0.53) | MAPTRAB9AKDM4ENPC1JUN | |
| SCHEMBL10620820 | 0.81 | TBXAS1 (0.62) | MAPTRAB9AKDM4ENPC1JUN | |
| SCHEMBL10620831 | 0.81 | TBXAS1 (0.62) | MAPTRAB9AKDM4ENPC1JUN | |
| SCHEMBL113959 | 0.80 | IDO1 (0.58) | MAPTCACNA1BCYP1A2CYP2D6LMNA | |
| SCHEMBL113958 | 0.80 | IDO1 (0.58) | MAPTCACNA1BCYP1A2CYP2D6LMNA | |
| SCHEMBL5856287 | 0.80 | MAPT (0.51) | MAPTRAB9AKDM4ENPC1JUN | |
| SCHEMBL5856291 | 0.80 | MAPT (0.51) | MAPTRAB9AKDM4ENPC1JUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | claimed |
| EP-2751076-B1 | SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES | MEDIMMUNE LTD (GB) | 2018-04-25 | — | — | EP | claimed |
| EP-2558445-B1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES | MEDIMMUNE LTD (GB) | 2017-03-22 | — | — | EP | claimed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2024-03-07 | — | — | US | disclosed |
| EP-3615544-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| EP-4101855-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11773219-B2 | Functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-20140303367-A1 | Methods for Synthesizing Molybdopterin Precursor Z Derivatives | ALEXION PHARMA INTERNATIONAL SÀRL (CH) | 2014-10-09 | — | — | US | disclosed |
| US-8846941-B2 | Functionalized polymers | QUIAPEG AB (SE) | 2014-09-30 | — | — | US | disclosed |
| WO-2014060575-A2 | PROCESS FOR THE ENANTIOSELECTIVE SYNTHESIS OF A TETRAHYDROBENZAZEPINE COMPOUND | MEDICHEM S.A. (ES) | 2014-04-24 | — | — | WO | disclosed |
| US-20140030278-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | QUIAPEG AB (SE) | 2014-01-30 | — | — | US | disclosed |
| EP-2675278-A1 | METHODS FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES | Alexion Pharma International SARL (CH) | 2013-12-25 | — | — | EP | disclosed |
| WO-2013186632-A2 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | QUIAPEG AB (SE) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013160728-A1 | DUAL TARGETING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA (IT) | 2013-10-31 | — | — | WO | disclosed |
| WO-2012112922-A1 | METHODS FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES | ALEXION PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20120178940-A1 | Functionalized Polymers | QUIAPEG AB (SE) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303367-A1 | Methods for Synthesizing Molybdopterin Precursor Z Derivatives | MTHFD2, ADH1B, DPYD | MAPT 3015/4885RAB9A 2108/4885KDM4E 3761/4885 |
| US-20120178940-A1 | Functionalized Polymers | PARG, PUF60, PCBP1 | MAPT 491/4885RAB9A 2986/4885KDM4E 3714/4885 |
| US-11773219-B2 | Functionalized polymers | PARG, PUF60, PCBP1 | MAPT 491/4885RAB9A 2986/4885KDM4E 3714/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | MAPT 8/4885RAB9A 1351/4885KDM4E 2083/4885 |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | MAPT 1800/4885RAB9A 3451/4885KDM4E 4028/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | MAPT 4519/4885RAB9A 1941/4885KDM4E 3931/4885 |
| US-20140030278-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | MAPT 1800/4885RAB9A 3451/4885KDM4E 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.